ERBB2 and breast carcinoma: Curigliano, G has shown a keen interest in the mechanisms of immune escape in HER2-positive breast cancer and triple-negative breast cancer (TNBC), potential targets for immunotherapy, identification of tumor-associated antigens, and the application of biomarkers in immunotherapy, with a particular emphasis on immune checkpoint inhibitors (ICIs) (50–53).